PT - JOURNAL ARTICLE AU - Joonatan Palmu AU - Jeramie D. Watrous AU - Kysha Mercader AU - Aki S. Havulinna AU - Kim A. Lagerborg AU - Aaro Salosensaari AU - Mike Inouye AU - Martin G. Larson AU - Jian Rong AU - Ramachandran S. Vasan AU - Leo Lahti AU - Allen Andres AU - Susan Cheng AU - Pekka Jousilahti AU - Veikko Salomaa AU - Mohit Jain AU - Teemu J. Niiranen TI - Eicosanoid Inflammatory Mediators Are Robustly Associated with Blood Pressure in the General Population AID - 10.1101/2020.02.08.20021022 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.08.20021022 4099 - http://medrxiv.org/content/early/2020/02/11/2020.02.08.20021022.short 4100 - http://medrxiv.org/content/early/2020/02/11/2020.02.08.20021022.full AB - Background Epidemiologic and animal studies have associated systemic inflammation with blood pressure (BP). However, the mechanistic factors linking inflammation and BP remain unknown. Fatty acid derived eicosanoids serve as mediators of inflammation and have been suggested to also regulate renal vascular tone, peripheral resistance, renin-angiotensin system, and endothelial function. We therefore hypothesize that specific pro- and anti-inflammatory eicosanoids modulate BP.Methods In N=8099 FINRISK 2002 cohort participants randomly drawn from the Finnish population register (53% women, mean age 48±13 years), we profiled 545 distinct high-quality eicosanoids and related oxylipin mediators in plasma using non-targeted liquid chromatography-mass spectrometry. In models adjusted for conventional hypertension risk factors, we analyzed the associations of eicosanoids and eicosanoid profiles with systolic BP and hypertension. We used the Framingham Heart Study (FHS) Offspring study (N=2859) as the replication cohort.Results We observed 187 eicosanoids (34%) significantly associated with systolic BP (P < Bonferroni-corrected threshold of 0.05/545). 175 of these associations were positive and 12 were negative. Due to strong correlations between the eicosanoids, we used forward selection linear regression modeling to identify six eicosanoids independently related to systolic BP. A risk score based on these six eicosanoids was related to 40% (95% confidence interval [CI], 33–48%) and 32% (95% CI, 21–44%) greater odds of hypertension in FINRISK and FHS, respectively, per 1-SD score increase. Individuals in the upper quartile of the six-eicosanoid risk score had 2.26-fold greater odds (95% CI, 1.96–2.62) of prevalent hypertension in FINRISK, compared with those in the lowest quartile. These findings were successfully replicated in an independent cohort of FHS participants.Conclusions Plasma eicosanoids demonstrate strong associations with BP in the general population. Intriguingly, we observed specific protective molecules as well as harmful molecules. As eicosanoid compounds affect numerous physiological processes that are central to BP regulation, they may offer new insights regarding pathogenesis of hypertension, as well as serve as new targets for therapeutic intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Emil Aaltonen Foundation (TN), the Paavo Nurmi Foundation (TN), the Finnish Medical Foundation (TN), the Academy of Finland (grant n:o 321351 to TN; 295741, 307127 to LL, 321356 to ASH), Ellison Foundation (SC) and the National Heart, Lung and Blood Institute’s Framingham Heart Study (contracts N01HC25195 and HHSN268201500001I), and the following National Institutes of Health grants: R01HL093328 (RSV), R01HL107385 (RSV), R01HL126136 (RSV), R00HL107642 (SC), R01HL131532 (SC), R01HL134168 (SC, MJ), R01HL143227 (SC, MJ), R01ES027595 (MJ, SC), and K01DK116917 (JDW). The funders play no role in the design of the study; the collection, analysis, and interpretation of the data; and the decision to approve publication of the finished manuscript. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available at THL Biobank (https://thl.fi/en/web/thl-biobank) except for LQ/MS data that is being prepared for publication.